Algiax Pharmaceuticals is a clinical-stage biotechnology company established in 2011. It is dedicated to the discovery and development of innovative products to treat diseases with a high unmet medical need.
Algiax’ lead candidate AP-325 is in clinical development for the treatment of neuropathic pain.
AP-325 is a small-molecule GABAA receptor modulator in clinical development as a therapy for neuropathic pain. Algiax is currently preparing a Phase 2 study in subjects with chronic neuropathic pain after peripheral nerve injury.
Next to AP-325 Algiax has discovered novel GABAA receptor modulator compounds called Thioacrylamide (ThAc) derivatives. The company is advancing a selection of ThAcs derivatives from its discovery to preclinical characterization. The main focus area for these novel compounds will be the treatment of Diabetes.
Algiax’ strategy is to develop its drug candidates up to a Clinical Phase II-III stage and out-license them to pharmaceutical and biotech companies for further clinical development and market authorization.
For additional information, please visit www.algiax.com.